The NeurologyLive® Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) clinical focus page is a concentrated place for the latest information on the care and management of patients with CIDP. This page includes podcasts, videos and expert interviews, and news about the latest study and clinical trial findings, FDA actions, and clinical guideline updates.
March 19th 2025
The company recently announced positive topline results from its phase 3 study in patients with MG and initial data from its phase 2b study in patients with CIDP, both assessing batoclimab.
Japan's Ministry of Health, Labour and Welfare Grants Regulatory Approval to Efgartigimod for CIDP
January 28th 2025Previously, Argenx's efgartigimod alfa and hyaluronidase-qvfc was granted orphan drug designation for the treatment of chronic inflammatory demyelinating polyneuropathy in Japan.
Early Immunotherapy May Be Crucial to Prevent Axonal Damage in CIDP, Study Suggests
Published: January 20th 2025 | Updated: February 3rd 2025A new study highlighted the importance of initiating immunotherapy promptly in chronic inflammatory demyelinating polyneuropathy to prevent axonal damage and disability progression.
Understanding the Critical and Emerging Role of Complement in Neurological Disorders
December 23rd 2024The complement system is critical in immune defense and tissue homeostasis, but its dysregulation can contribute to autoimmune neurological disorders and neurodegenerative diseases like Alzheimer, ALS, and multiple sclerosis.
FDA Clears Phase 2 MoMeNtum Trial of DNTH103 in Multifocal Motor Neuropathy
August 6th 2024MoMeNtum will evaluate the efficacy and safety of DNTH103, administered subcutaneously every two weeks over a 17-week period, followed by a 52-week open-label extension to collect additional safety and efficacy data.
Both Sides Now: The Before and After of CIDP’s Diagnostic Journey
Published: May 30th 2024 | Updated: May 30th 2024Crystal, a patient living with chronic inflammatory demyelinating polyneuropathy and one of the faces of the Shining Through CIDP awareness campaign, discussed the diagnostic challenges associated with the rare disease.
NeuroVoices: Kayla Scippa, on Recognizing Unmet Need in Chronic Demyelinating Polyneuropathy
Published: May 8th 2024 | Updated: May 8th 2024The associate director, Patient Reported Outcomes, Johnson & Johnson, provided clarity on a poster presentation from AAN 2024 examining the most critical aspects to CIDP disease severity.